NCT00083278

Study of MDX-010 in Stage IV Breast Cancer

A Phase II Study of MDX-010 in Patients With Stage IV Adenocarcinoma of the Breast

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 33 (actual)
• Sponsor: Bristol-Myers Squibb · Industry
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This Phase II study is designed to treat patients who have been diagnosed with Stage IV Breast Cancer, which has progressed despite treatment with primary therapies, including hormonal therapy, chemotherapy, and antibody therapy. Thirty-three patients will be treated with the monoclonal antibody MDX-010. The initial antitumor activity profile of MDX-010 will be determined, as well as identification of the induction of any antitumor immunity following the MDX-010 treatment.

Conditions

• Breast Cancer
• Adenocarcinoma

Interventions

Type	Name	Description
DRUG	MDX-010

Timeline

• Start date: 2003-05-01
• Completion: 2006-02-01
• First posted: 2004-05-20
• Last updated: 2012-04-27

Locations

14 sites across 1 country: United States